Physician profile
Regina E Robison
NPI 1316269871
$1,639.20
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.52 · 2022: $411 · 2023: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $319.89 | 2021-2023 | Caplyta |
| Abbvie INC. | $284.78 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $278.86 | 2022-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $230.36 | 2022-2023 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $222.14 | 2021-2023 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $114.54 | 2023 | Ingrezza |
| Axsome Therapeutics, INC. | $96.94 | 2023 | Auvelity |
| Sunovion Pharmaceuticals INC. | $31.26 | 2021 | |
| Pfizer INC. | $16.77 | 2023 | |
| Lundbeck LLC | $15.55 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.14 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.